iNET Interactive - Online Advertising Agency
          
   Home    Authors    About    Login    Contact Us
   Search:   
Advanced Search     
  Articles

  Directories (11)
  Google (118)
  Interviews (9)
  Keywords (30)
  Link Development (40)
  Marketing (48)
  Meta Tags (7)
  Optimization (112)
  Promotion (30)
  SE News (861)
  Spiders & Robots (22)
  Submission (8)
  Traffic Analysis (6)
  Tools (7)
  Algorithm (11)
  PPC (17)
  Domain Names (6)
  SEO Services (40)
 
Want to receive new articles via e-mail? Click here!
/Home /SE News

eResearch Reports Third Quarter 2007 Results 

  Views:    258
  Votes:    0
by TechPad Agency 12/13/07 Rating: 

Synopsis:

eResearchTechnology, Inc. (eRT), has revealed its results for the third quarter of 2007 and nine-month period ending September 30, 2007.
Pages: 
The Article

Philadelphia, Pennsylvania - (Website Hosting Directory) - December 13, 2007 - eResearchTechnology, Inc. (eRT), has revealed its results for the third quarter of 2007 and nine-month period ending September 30, 2007.

Dr. Michael McKelvey, President and CEO of eRT remarked, ''We are pleased with our third quarter results. Our Company demonstrated strong growth during the quarter, led by our core cardiac safety business. Both our volume and new bookings growth of 40% in the quarter were impressive. The third quarter is a seasonally slow period due to vacations and the tendency of sponsors to not initiate Thorough ECG trials in the summer months. We were able to leverage our SG and A structure to produce net income growth of 50.3% compared to the same quarter a year ago; year to date our net income is up 66.4% from the previous year. Our earnings per diluted share have already exceeded that attained in all of 2006.''

Highlights of the Third Quarter were: -- ECG volume was up 40% in the third quarter of 2007 compared to the same quarter a year ago; -- $35.5 million in new bookings of contracts and work orders, an increase of 40.3% from the same quarter a year ago; -- Seven new Thorough ECG study agreements were signed, valued at approximately $7.2 million, translating into an average Thorough ECG study size of more than $1 million. -- Backlog increased to $115.0 million as of September 30, 2007. An increase of 23.4% from the same quarter a year ago. The annualized cancellation rate for the quarter was 13.4%. -- The book-to-bill ratio for the third quarter was 1.5, an increase from the previous quarter's book-to-bill ratio of 1.4 and from the book to bill ratio of 1.1 for the third quarter of 2006. -- The newly-formed Consulting Practice recorded significant new sales and bookings; and ePro, which was initiated in June of this year, recorded its first sales bookings.

The Company reported revenues of $24.0 million for the third quarter of 2007, a 7.9% increase from $22.2 million in the third quarter of 2006, which included $1.2 million for the ending of a franchise agreement during the same period in 2006. The Company reported net income of $3.7 million for the third quarter of 2007, a 50.3% increase from $2.5 million in the third quarter of 2006. This resulted in net income per diluted share of $0.07 in the third quarter of 2007, compared to $0.05 in the third quarter of 2006.

The Company's gross margin percentage in the third quarter of 2007 was 48.0% compared to 49.2% in the third quarter of 2006. As previously noted, the third-quarter of 2006 included revenue of $1.2 million for the ending of a franchise agreement; without which the third quarter of 2006 gross margin would have been 46.3%. Pre-tax income margin in the third quarter of 2007 was 24.8% compared to 17.4% in the third quarter of 2006. The Company's tax rate for the third quarter of 2007 was 37.7% compared to 36.3% in the third quarter of 2006.

For the nine months ended September 30, 2007, the Company reported revenues of $69.8 million compared to $66.4 million for the nine months ended September 30, 2006. The Company reported net income of $10.1 million, or $0.20 per diluted share, for the nine months ended September 30, 2007 compared to net income of $6.1 million, or $0.12 per diluted share, for the nine months ended September 30, 2006.

The Company's gross margin percentage for the nine months ended September 30, 2007 was 49.9% compared to 49.1% for the nine months ended September 30, 2006. Pre-tax income margin for the nine months ended September 30, 2007 was 23.5% compared to 14.9% for the nine months ended September 30, 2006. The Company's tax rate was 38.5% for the nine months ended September 30, 2007 compared to 38.6% for the nine months ended September 30, 2006. eRT ended the quarter with $71.0 million in cash, cash equivalents and investments, an increase of $7.6 million from $63.4 million at the end of the second quarter of 2007.

Dr. McKelvey added, ''The 23.4% growth in our backlog to $115.0 million from a year ago, combined with a continued robust sales environment and stabilizing prices shows a solid market demand for our services. We were particularly pleased with the strong showing of our bookings, which showed the fourth quarter in a row of growth quarter over quarter, and the growth of our newly-formed consulting business. In addition, we are working more closely with some of our key CRO partners in a number of different areas. Our operations team is executing very well and we continue to make good progress on the expense line; while we continue to invest in eClinical, Consulting and ePRO. The net effect of this is our achievement of pre-tax margins of 24.8% for the third quarter of 2007.''

The Company issued guidance for the fourth quarter of 2007. eRT anticipates revenues of between $27 million and $28.5 million and net income per diluted share of $0.09 to $0.11 for the fourth quarter ending December 31, 2007. For the full year ending December 31, 2007, management anticipates revenues will be around the midpoint of the previously issued guidance of $95 million and $103 million. Management raised its anticipated net income per diluted share to $0.29 to $0.31 from the previously issued guidance of the high end of the range of $0.25 to $0.30.

Based in Philadelphia, PA, eResearchTechnology, Inc. is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

To learn more, please visit: www.ert.com.



                                                  Locate a top web host and offers here.








Pages: 

Similar/related articles:


 
  Sponsors